Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
entrez:
11
12
2020
pubmed:
12
12
2020
medline:
16
7
2021
Statut:
ppublish
Résumé
We explored predictors of CD4/CD8 ratio improvement and optimal immunological recovery (OIR) after initiation of antiretroviral therapy (ART) in naive people living with HIV (PLWH). Retrospective multicenter study including naive PLWH starting ART with 2 nucleos(t)ide reverse transcriptase inhibitors + 1 integrase strand transfer inhibitor (InSTI) or non-NRTI or protease inhibitor (PI). PLWH were followed from the time of ART initiation (baseline) to the discontinuation of first-line regimen, virological failure, death, or loss to follow-up. Estimated incidence and predictors of time to CD4/CD8 ratio normalization (defined as ≥1) and OIR (defined as CD4/CD8 ratio ≥ 1 plus CD4 ≥ 500 cells/µL plus CD4% ≥ 30%) were explored by Kaplan-Meier curves and Cox regression analysis. Overall, 1428 PLWH (77.8% males, median age 39 years, 55.1% with positive cytomegalovirus (CMV) antibodies, median HIV-RNA 4.80 log copies/mL, median CD4 323 cells/µL, median CD4/CD8 ratio 0.32) were included, of which 21.5% (n = 307), 44.5% (n = 636), and 34% (n = 485) treated with InSTI-, PI-, and NNRTI-based regimens, respectively. The estimated proportion of CD4/CD8 normalization and OIR at 36 months was 38.6% and 32.9%, respectively. Multivariate analysis showed that InSTI-based regimens had a higher probability of CD4/CD8 ratio normalization and OIR both in the total population (P < 0.001 versus PI) and in advanced naive PLWH (P ≤ 0.001 versus PI and NNRTI). Moreover, subjects with positive CMV serology showed a lower probability of CD4/CD8 ratio normalization and OIR (P < 0.001). InSTI-based regimens showed a better immune recovery, suggesting that the type of first-line ART can influence immune reconstitution. PLWH with positive CMV serology showed an increased risk of suboptimal immune recovery.
Sections du résumé
BACKGROUND
We explored predictors of CD4/CD8 ratio improvement and optimal immunological recovery (OIR) after initiation of antiretroviral therapy (ART) in naive people living with HIV (PLWH).
METHODS
Retrospective multicenter study including naive PLWH starting ART with 2 nucleos(t)ide reverse transcriptase inhibitors + 1 integrase strand transfer inhibitor (InSTI) or non-NRTI or protease inhibitor (PI). PLWH were followed from the time of ART initiation (baseline) to the discontinuation of first-line regimen, virological failure, death, or loss to follow-up. Estimated incidence and predictors of time to CD4/CD8 ratio normalization (defined as ≥1) and OIR (defined as CD4/CD8 ratio ≥ 1 plus CD4 ≥ 500 cells/µL plus CD4% ≥ 30%) were explored by Kaplan-Meier curves and Cox regression analysis.
RESULTS
Overall, 1428 PLWH (77.8% males, median age 39 years, 55.1% with positive cytomegalovirus (CMV) antibodies, median HIV-RNA 4.80 log copies/mL, median CD4 323 cells/µL, median CD4/CD8 ratio 0.32) were included, of which 21.5% (n = 307), 44.5% (n = 636), and 34% (n = 485) treated with InSTI-, PI-, and NNRTI-based regimens, respectively. The estimated proportion of CD4/CD8 normalization and OIR at 36 months was 38.6% and 32.9%, respectively. Multivariate analysis showed that InSTI-based regimens had a higher probability of CD4/CD8 ratio normalization and OIR both in the total population (P < 0.001 versus PI) and in advanced naive PLWH (P ≤ 0.001 versus PI and NNRTI). Moreover, subjects with positive CMV serology showed a lower probability of CD4/CD8 ratio normalization and OIR (P < 0.001).
CONCLUSIONS
InSTI-based regimens showed a better immune recovery, suggesting that the type of first-line ART can influence immune reconstitution. PLWH with positive CMV serology showed an increased risk of suboptimal immune recovery.
Identifiants
pubmed: 33306566
doi: 10.1097/QAI.0000000000002525
pii: 00126334-202101010-00017
doi:
Substances chimiques
Anti-HIV Agents
0
HIV Protease Inhibitors
0
Integrase Inhibitors
0
Reverse Transcriptase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
119-127Références
Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946–954.
Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–129.
Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010;55:262–270.
Rönsholt FF, Ullum H, Katzenstein TL, et al. T-cell subset distribution in HIV-1-infected patients after 12 years of treatment-induced viremic suppression. J Acquir Immune Defic Syndr. 2012;61:270–278.
Hsu DC, Sereti I, Ananworanich J. Serious Non-AIDS events: immunopathogenesis and interventional strategies. AIDS Res Ther. 2013;10:29.
Bruno G, Saracino A, Monno L, et al. The revival of an “old” marker: CD4/CD8 ratio. AIDS Rev. 2017;19:81–88.
Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10:e1004078.
Serrano-Villar S, Pérez-Elías MJ, Dronda F, et al. Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio. PLoS One 2014;9:e85798.
Serrano-Villar S, Moreno S, Fuentes-Ferrer M, et al. The CD4: CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery. HIV Med. 2014;15:40–49.
Mussini C, Lorenzini P, Cozzi-Lepri A, et al. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV 2015;2:e98–e106.
Guiguet M, Kendjo E, Carcelain G, et al. CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells/mm3. Antivir Ther. 2009;14:451–457.
Hocqueloux L, Avettand-fènoël V, Jacquot S, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother. 2013;68:1169–1178.
Muscatello A, Nozza S, Fabbiani M, et al. Enhanced immunological recovery with early start of antiretroviral therapy during acute or early HIV Infection–Results of Italian Network of ACuTe HIV InfectiON (INACTION) retrospective study. Pathog Immun. 2020;5:8–33.
De Salvador-Guillouët F, Sakarovitch C, Durant J, et al. Antiretroviral regimens and CD4/CD8 ratio normalization in HIV-infected patients during the initial year of treatment: a cohort study. PLoS One. 2015;10:1–12.
Masiá M, Padilla S, Barber X, et al. Comparative impact of suppressive antiretroviral regimens on the CD4/CD8 T-cell ratio: a cohort study. Medicine (Baltimore) 2016;95:1–6.
Serrano-Villar S, Zhou Y, Rodgers AJ, et al. Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients. J Antimicrob Chemother. 2017;72:235–239.
Herrera S, Fernandez-Felix BM, Hunt PW, et al. Impact of first-line antiretroviral therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort. J Antimicrob Chemother. 2020;75:1604–1610.
Milanés-Guisado Y, Gutiérrez-Valencia A, Muñoz-Pichardo JM, et al. Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients? J Antimicrob Chemother. 2020;75:200–207.
Taramasso L, Fabbiani M, Nozza S, et al. Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort. HIV Med. 2020;21:523–535.
Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871–1879.
Kigozi BK, Sumba S, Mudyope P, et al. The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda. AIDS Res Ther. 2009;6:15.
Cingolani A, Lepri AC, Castagna A, et al. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition. Clin Infect Dis. 2012;54:853–861.
Stuehler C, Bernardini C, Elzi L, et al. Immune recovery in HIV-infected patients after Candida esophagitis is impaired despite long-term antiretroviral therapy. AIDS. 2016;30:1923–1933.
Fabbiani M, Gagliardini R, Ciccarelli N, et al. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018;73:1955–1964.
ECDC, WHO Regional Office for Europe. HIV/AIDS Surveillance in Europe 2019—2018 Data. 2019. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/hiv-surveillance-report-2019.pdf . Accessed November 11, 2020.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Adults and adolescents living with HIV guidelines for the use of antiretroviral agents in adults and adolescents living with HIV developed by the DHHS panel on antiretroviral guidelines for adults. Dep Heal Hum Serv. 2019:1–378. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/GLChunk_37.pdf . Accessed November 11, 2020.
Torti C, Prosperi M, Motta D, et al. Factors influencing the normalization of CD4+T-cell count, percentage and CD4+/CD8+T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. Clin Microbiol Infect. 2012;18:449–458.
Lake J, Mccomsey GA, Hulgan T, et al. Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial. HIV Med. 2014;15:431–441.
Lombardi F, Belmonti S, Borghetti A, et al. Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients. HIV Res Clin Pract. 2019;20:92–98.
Fabbiani M, Mondi A, Colafigli M, et al. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RAST. Scand J Infect Dis. 2014;46:34–45.
Gatell JM, Assoumou L, Moyle G, et al. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS. 2017;31:2503–2514.
Patterson KB, Prince HA, Stevens T, et al. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS. 2013;27:1413–1419.
Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–1371.
Younas M, Psomas C, Reynes C, et al. Microbial translocation is linked to a specific immune activation profile in HIV-1-Infected adults with suppressed viremia. Front Immunol. 2019;10:2185.
Caby F, Guihot A, Lambert-Niclot S, et al. Determinants of a low CD4/CD8 ratio in HIV-1-infected individuals despite long-term viral suppression. Clin Infect Dis. 2016;62:1297–1303.
Poizot-Martin I, Allavena C, Duvivier C, et al. CMV+ serostatus associates negatively with CD4:CD8 ratio normalization in controlled HIV-infected patients on cART. PLoS One. 2016;11:e0165774.
Smith DM, Nakazawa M, Freeman ML, et al. Asymptomatic CMV replication during early Human Immunodeficiency Virus (HIV) infection is associated with lower CD4/CD8 ratio during HIV treatment. Clin Infect Dis. 2016;63:1517–1524.
Hunt PW, Martin JN, Sinclair E, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD41 T cell recovery on antiretroviral therapy. J Infect Dis. 2011;203:1474–1483.
Lichtner M, Cicconi P, Vita S, et al. Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. J Infect Dis. 2015;211:178–186.
Dowd JB, Aiello AE, Alley DE. Socioeconomic disparities in the seroprevalence of cytomegalovirus infection in the US population: NHANES III. Epidemiol Infect. 2009;137:58–65.
Phanuphak P, Lo YR. Implementing early diagnosis and treatment: programmatic considerations. Curr Opin HIV AIDS. 2015;10:69–75.
Gianella S, Moser C, Vitomirov A, et al. Presence of asymptomatic cytomegalovirus and Epstein--Barr virus DNA in blood of persons with HIV starting antiretroviral therapy is associated with non-AIDS clinical events. AIDS. 2020;34:849–857.